Topic: Neuroendocrine Tumors

Download All Articles

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 7 Aug 2016

Share This Special Issue

Guest Editor(s)

  • Rossana Berardi, MD
    Head of Dept of Medical Oncology, Director of the Postgraduate School of Medical Oncology, Director of “Genetic Cancer” Center, Deputy Director of Department of Clinical and Molecular Science, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Via Conca 71, 60126 Ancona, Italy.

    Website | E-mail

Special Issue Introduction:

This special issue on neuroendocrine neoplasms aims to summarize the present knowledge about the treatment of these tumors highlighting available evidences as well as new biological perspectives on biological and targeted therapies, also including case reports.

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 7 Aug 2016
Contacts: Dandan Yu, Managing Editor,

Published Articles Download All Articles
  • Review of recent advances in medical treatment for neuroendocrine neoplasms: somatostatin analogs and chemotherapy

    Francesca Spada , Monica Valente
    Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare tumours often producing high levels of hormones and causing symptoms. There are a number of different types of NENs. They usually arise as advanced and low/intermediate grade only in a minority of cases, as high grade. Treatment depends on which type and may include surgery, interventional radiology, and systemic treatment,... Read more
    J Cancer Metastasis Treat 2016;2:313-20. | doi:10.20517/2394-4722.2016.38
    Published on: 31 Aug 2016  | Viewed:8608  | Downloaded:533
    +HTML| PDF
  • Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus

    Paola Razzore , Giorgio Arnaldi
    Neuroendocrine neoplasms (NETs) are rare tumors that are increasing in incidence. NETs are characterized by heterogeneous biological behaviour, clinical presentation and course. A sensitive and specific diagnostic and prognostic circulating biomarker useful for all sites, grading and staging of neuroendocrine tumors is still an unmet need. The aim of this article was to review current... Read more
    J Cancer Metastasis Treat 2016;2:348-56. | doi:10.20517/2394-4722.2016.39
    Published on: 31 Aug 2016  | Viewed:4767  | Downloaded:463
    +HTML| PDF
  • Orbital lesions, an exceedingly rare site of neuroendocrine tumor metastasis

    Sara Pusceddu , Massimo Milione , Silvia Ortolani , Alessio Pellegrinelli , Marco Brugia , Filippo de Braud , Lorenzo Antonuzzo
    Neuroendocrine tumors are rare neoplasms arising primarily in the gastrointestinal tract and lung. The liver is the most common site of metastases, but these tumors can rarely metastasize to atypical sites. Surgery is the only curative approach while the optimal medical treatment is debated. From this perspective, a multidisciplinary approach for each single case becomes very important. In this... Read more
    J Cancer Metastasis Treat 2016;2:341-4. | doi:10.20517/2394-4722.2016.41
    Published on: 31 Aug 2016  | Viewed:2459  | Downloaded:174
    +HTML| PDF
  • Pancreatic neuroendocrine tumor with hypoglycemia and elevated insulin-like growth factor II: a case report

    Roberta Modica , Antonella Di Sarno , Annamaria Colao , Antongiulio Faggiano
    Pancreatic neuroendocrine tumors (pNETs) can be associated with different clinical syndromes. Insulinoma is the most common functioning pNET characterized by hypoglycemia and hyperinsulinemia. The authors report a case of a man presenting with hypoglycemia and biochemical features of insulinoma. A pancreatic lesion was found and growth hormone (GH) deficiency was also diagnosed associated with... Read more
    J Cancer Metastasis Treat 2016;2:345-7. | doi:10.20517/2394-4722.2016.44
    Published on: 31 Aug 2016  | Viewed:2457  | Downloaded:190
    +HTML| PDF
  • Medical therapy for advanced gastro-entero-pancreatic and bronchopulmonary neuroendocrine tumors

    Mariangela Torniai , Silvia Rinaldi , Francesca Morgese , Giulia Ricci , Azzurra Onofri , Christian Grohé , Rossana Berardi
    Neuroendocrine tumors (NETs) represent a spectrum of rare neoplasms arising in different organism sites. Depending on the site of onset, they also can be distinguished using lab exams (secreting vs. nonsecreting), clinical symptoms (functioning vs. nonfunctioning), behavioral, morphological characteristics (tumor cells’ architectural growth patterns, mitotic and Ki-67 index, presence of... Read more
    J Cancer Metastasis Treat 2016;2:329-40. | doi:10.20517/2394-4722.2016.47
    Published on: 31 Aug 2016  | Viewed:5270  | Downloaded:230
    +HTML| PDF
  • Double tracer PET/CT: what is it and what does it mean?

    Mattia Pellicciari , Silvia Ortolani , Elisabetta Grego , Giampaolo Tortora , Sara Cingarlini
    68Ga-DOTA-peptide PET/CT is a recommended imaging modality in the workup of neuroendocrine neoplasms (NENs), which shows high diagnostic sensitivity and is a strong predictor of successful somatostatin receptor directed treatments. Although not routinely recommended, reliable evidences show that 18F-FDG PET/CT can provide complementary information in this setting with the ability to... Read more
    J Cancer Metastasis Treat 2016;2:321-8. | doi:10.20517/2394-4722.2016.45
    Published on: 31 Aug 2016  | Viewed:1436  | Downloaded:185
    +HTML| PDF
  • Neuroendocrine tumors: current therapies, notch signaling, and cancer stem cells

    Judy S. Crabtree , Lucio Miele
    Neuroendocrine tumors (NETs) encompass a broad spectrum of malignancies all derived from neuroendocrine cell lineage, affecting many different organs including the gastrointestinal (GI) tract, the endocrine pancreas, the thyroid, the skin and the respiratory tract. These tumors as a group are very heterogeneous, with varying characteristics attributed to each tissue of origin and tumor subtype.... Read more
    J Cancer Metastasis Treat 2016;2:279-93. | doi:10.20517/2394-4722.2016.30
    Published on: 17 Aug 2016  | Viewed:2428  | Downloaded:364
    +HTML| PDF
  • Management of hepatic metastases of well/moderately differentiated neuroendocrine tumors of the digestive tract

    Anna La Salvia , Stefano Partelli , Marco Tampellini , Domenico Tamburrino , Massimo Falconi , Giorgio V. Scagliotti , Maria Pia Brizzi
    In neuroendocrine tumors (NETs), liver metastases (LM) represent the most crucial prognostic factor, irrespective of the primary tumor site. At diagnosis, about 65-95% of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show hepatic metastasis. Management strategies of LM are heterogeneous and range from systemic therapy to liver-directed procedures. The type of systemic therapy used is... Read more
    J Cancer Metastasis Treat 2016;2:294-303. | doi:10.20517/2394-4722.2016.37
    Published on: 17 Aug 2016  | Viewed:6443  | Downloaded:405
    +HTML| PDF
  • Controversies in the treatment of digestive neuroendocrine tumors

    Maria Rinzivillo , Francesco Panzuto , Gianfranco Delle Fave
    Gastroenteropancreatic neuroendocrine tumors (NETs) have an incidence of 2.39 per 100,000 inhabitants per year, and a prevalence of 35 cases per 100,000 inhabitants; the gap between these rates is due to the relatively long survival time of these tumors, which can be thus considered as chronic oncological diseases. Recently, more therapeutic options have become available, but criteria for... Read more
    J Cancer Metastasis Treat 2016;2:304-9. | doi:10.20517/2394-4722.2016.40
    Published on: 17 Aug 2016  | Viewed:1985  | Downloaded:206
    +HTML| PDF
  • Merkel cell carcinoma responsive to Etoposide: a case report and brief literature review

    Chiara Ancona , Andrea Caff , Giovanni Manfredi Assanto , Stefano Cordio
    Merkel cell carcinoma (MCC), first described in 1972, is an aggressive primary cutaneous carcinoma able to incorporate both epithelial and neuroendocrine features. MCC mainly appears in individuals in their eighth decade and it is related to a high mortality rate. The etiology of this rare disease is not well-understood but ultraviolet radiation exposure, immune suppression, and aging have a... Read more
    J Cancer Metastasis Treat 2016;2:310-2. | doi:10.20517/2394-4722.2016.46
    Published on: 17 Aug 2016  | Viewed:4582  | Downloaded:149
    +HTML| PDF
  • Neuroendocrine tumors: a multidisciplinary approach for a complex disease

    Rossana Berardi
    J Cancer Metastasis Treat 2016;2:277-8. | doi:10.20517/2394-4722.2016.50
    Published on: 17 Aug 2016  | Viewed:2643  | Downloaded:238
    +HTML| PDF
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.